The glimmer of hope for a vaccine moved the New York Stock Exchange this Friday. After three weeks of consecutive declines, this news saved Wall Street from a 4th week of decline. As a result, the leading indices have reached new highs. The Nasdaq gained 2.3%, the Dow Jones climbed 1.3% and the S&P500 gained 1.6%.
Intraday, the Nasdaq jumped +3% in a straight line. On the weekly time-frame, while it was down -1% on Friday morning, the index reversed the trend with an increase of 1.2% for the week.
Moreover, this succession was encouraged by the GAFAM. Indeed, the latter were supported by certain pharmaceutical titles such as Novavacs and Moderna, which experienced a growth of more than 6%. Similarly, the announcement by Johnson & Johnson did not fail to arouse investor interest.
News about Johnson & Johnson's new coronavirus vaccine is good. Initial results from a Phase 1/2a clinical trial suggest that a single dose may have caused a strong immune response in each of the 800 volunteer participants. For the trial, two age groups were considered :
This trial looked at the side effects and safety of two different doses.
Following the study, the observed results show that the vaccine produces an immune response. It is now a safe vaccine and can be tested more broadly. The review has been published on MedRxiv but has not yet appeared in a medical journal.
It should also be noted that twenty-nine days after being vaccinated with the two different doses, patients developed antibodies against the virus. This includes 99 per cent of those between the ages of 18 and 55. There may have been subsequent side effects such as fatigue, aches, pains, headache or fever. However, it should be noted that these side effects were very mild and disappeared quickly.
A second injection is planned for some patients in the same trial. These patients will be injected with Ad26.COV2.S. This is a Johnson & Johnson vaccine that uses the same technology that was used for Ebola, HIV, RSV and Zika. These Phase 3 trials will investigate the efficacy and safety of a single dose. This, compared to placebo to prevent symptomatic Covid-19.
In addition, Johnson & Johnson has indicated its intention to register soon near 60 000 adult volunteers. These volunteers will be registered at more than 200 sites in the United States and around the world.